Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.

@article{Li2016SynthesisAB,
  title={Synthesis and biological evaluation of triazole based uracil derivatives as novel DPP-4 inhibitors.},
  author={Qing Li and Li Han and Bin Zhang and Jinpei Zhou and Huibin Zhang},
  journal={Organic \& biomolecular chemistry},
  year={2016},
  volume={14 40},
  pages={
          9598-9611
        }
}
A series of triazole based uracil derivatives were designed and synthesized as novel DPP-4 inhibitors. Compound A01 was identified as a lead compound for SAR studies focused on the structural modification at the S2' subsite of DPP-4. The novel analogues A02-A25 were obtained by modifying the substituents at the phenyl group, and B01-B09, by introducing the carbonyl group. On screening in DPP-4, compounds B03, B04 and B08 showed a significant improvement in DPP-4 inhibitory activities compared… 
View on PubMed
rsc.org
15 Citations
Background Citations
2
Methods Citations
1

15 Citations

Citation Type

Citation Type

Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors.
Optimization of the benzamide fragment targeting the S2' site leads to potent dipeptidyl peptidase-IV inhibitors.
Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors.
Design, synthesis and biological evaluation of novel 1,2,3-triazole-based xanthine derivatives as DPP-4 inhibitors
TLDR
A series of novel 1,2,3-triazole based xanthine derivatives were designed and evaluated for in vitro dipeptidyl peptidase-4 (DPP-4) activity and showed excellent inhibitory activity of DPP-4.
Surrogating and redirection of pyrazolo[1,5-a]pyrimidin-7(4H)-one core, a novel class of potent and selective DPP-4 inhibitors.
Structural optimization of pyrazolo[1,5-a]pyrimidine derivatives as potent and highly selective DPP-4 inhibitors.
Rapid generation of novel benzoic acid-based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: Scaffold-hopping and prodrug study.
Design, synthesis and anti-diabetic activity of novel 1, 2, 3-triazole-5-carboximidamide derivatives as dipeptidyl peptidase-4 inhibitors
Design, Synthesis and Molecular Docking Studies of Novel Indole–Isoxazole–Triazole Conjugates as Potent Antibacterial Agents
Abstract In search of better antibacterial agents, a series of novel 5-((aryl)methyl)-3-(1 H -indol-2-yl)isoxazole ( IIIa – e ) and 5-((3-chlorophenoxy)methyl)-3-(1-((1-(aryl)-1 H…
Recent progress of the development of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.
...
1
2
...

References

SHOWING 1-10 OF 19 REFERENCES
Discovery of a 3-pyridylacetic acid derivative (TAK-100) as a potent, selective and orally active dipeptidyl peptidase IV (DPP-4) inhibitor.
TLDR
In this work, novel pyridine derivatives containing a carboxy group were designed and interacted with the targeted amino acid residues around the catalytic region and thereby increased the inhibitory activity of dipeptidyl peptidase IV.
Design and synthesis of 3-pyridylacetamide derivatives as dipeptidyl peptidase IV (DPP-4) inhibitors targeting a bidentate interaction with Arg125.
A comparative study of the binding modes of recently launched dipeptidyl peptidase IV inhibitors in the active site.
Recent approaches to medicinal chemistry and therapeutic potential of dipeptidyl peptidase-4 (DPP-4) inhibitors.
8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes.
TLDR
1 (BI 1356), a highly potent, selective, long-acting, and orally active DPP-4 inhibitor that shows considerable blood glucose lowering in different animal species, is currently undergoing clinical phase IIb trials and holds the potential for once-daily treatment of type 2 diabetics.
Design, Synthesis, ADME Properties, and Pharmacological Activities of β‐Alanyl‐D‐histidine (D‐Carnosine) Prodrugs with Improved Bioavailability
TLDR
A drug discovery approach aimed at increasing the oral bioavailability of D‐CAR is reported, which designed, synthesized, and evaluated a series of novel lipophilic D‐ CAR prodrugs and selected the octyl ester of D‑CAR as a candidate for further pharmacological studies.
Design and synthesis of pyrimidinone and pyrimidinedione inhibitors of dipeptidyl peptidase IV.
TLDR
Two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyridinediones, are discovered and provide sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes.
Discovery of Novel P‐Glycoprotein‐Mediated Multidrug Resistance Inhibitors Bearing Triazole Core via Click Chemistry
TLDR
Compared with VRP, compound 5 exhibited more potency in increasing drug accumulation in K562/A02 MDR cells and persisted longer chemo‐sensitizing effect than VRP (<6 h) with reversibility, suggesting it may represent a promising candidate for developing P‐gp‐mediated MDR inhibitor.
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV.
TLDR
Alogliptin is a potent, selective inhibitor of the serine protease dipeptidyl peptidase IV (DPP-4) and related quinazolinone-based DPP-4 inhibitors provide sustained reduction of plasma D PP-4 activity and a lowering of blood glucose in animal models of diabetes.
A review of gliptins for 2014
  • A. Scheen
  • Medicine, Biology
    Expert opinion on pharmacotherapy
  • 2015
TLDR
An updated review providing an analysis of available recent data with commercialized DPP-4 inhibitors, with a special focus on differences between the various molecules, novelties regarding their mechanism of action and clinical efficacy.
...
1
2
...